U.S. Cerebral Infarction Treatment Market Size & Outlook
Related Markets
U.S. cerebral infarction treatment market highlights
- The U.S. cerebral infarction treatment market generated a revenue of USD 4,808.0 million in 2024 and is expected to reach USD 7,233.9 million by 2030.
- The U.S. market is expected to grow at a CAGR of 7% from 2025 to 2030.
- In terms of segment, tissue plasminogen activators (tpa) was the largest revenue generating drug class in 2024.
- Anticoagulants is the most lucrative drug class segment registering the fastest growth during the forecast period.
Cerebral infarction treatment market data book summary
| Market revenue in 2024 | USD 4,808.0 million |
| Market revenue in 2030 | USD 7,233.9 million |
| Growth rate | 7% (CAGR from 2025 to 2030) |
| Largest segment | Tissue plasminogen activators (tpa) |
| Fastest growing segment | Anticoagulants |
| Historical data | 2018 - 2023 |
| Base year | 2024 |
| Forecast period | 2025 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Tissue Plasminogen Activators (tPA), Anticoagulants, Antiplatelets, Anticonvulsants |
Other key industry trends
- In terms of revenue, U.S. accounted for 35.9% of the global cerebral infarction treatment market in 2024.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In North America, U.S. cerebral infarction treatment market is projected to lead the regional market in terms of revenue in 2030.
- Mexico is the fastest growing regional market in North America and is projected to reach USD 231.5 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Cerebral Infarction Treatment Market Scope
Cerebral Infarction Treatment Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Amneal Pharmaceuticals Inc Ordinary Shares - Class A | View profile | 7700 | 400 Crossing Boulevard, 3rd Floor, Bridgewater, NJ, United States, 08807 | https://www.amneal.com |
| Daiichi Sankyo Co Ltd | View profile | 17435 | 3-5-1, Nihonbashi-honcho, Chuo-ku, Tokyo, Japan, 103-8426 | https://www.daiichisankyo.com |
| Bristol-Myers Squibb Co | View profile | 34100 | Route 206 and Province Line Road, Princeton, New Jersey, NJ, United States, 08543 | https://www.bms.com |
| Sanofi SA | View profile | 87994 | 46, avenue de la Grande Armée, Paris, France, 75017 | https://www.sanofi.com |
| Pfizer Inc | View profile | 88000 | 66 Hudson Boulevard East, New York, NY, United States, 10001-2192 | https://www.pfizer.com |
| Otsuka Holdings Co Ltd | View profile | 39548 | 2-9 Kanda-Tsukasamachi, Chiyoda-ku, Tokyo, Japan, 101-0048 | http://www.otsuka.com/jp |
| Abbott Laboratories | View profile | 114000 | 100 Abbott Park Road, Abbott Park, IL, United States, 60064-6400 | https://www.abbottinvestor.com |
| Amgen Inc | View profile | 26700 | One Amgen Center Drive, Thousand Oaks, CA, United States, 91320-1799 | https://www.amgen.com |
| Novartis AG ADR | View profile | 76057 | Lichtstrasse 35, Basel, Switzerland, 4056 | https://www.novartis.com |
| Johnson & Johnson | View profile | 134400 | One Johnson and Johnson Plaza, New Brunswick, NJ, United States, 08933 | https://www.jnj.com |
U.S. cerebral infarction treatment market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to cerebral infarction treatment market will help companies and investors design strategic landscapes.
Tissue plasminogen activators (tpa) was the largest segment with a revenue share of 39.24% in 2024. Horizon Databook has segmented the U.S. cerebral infarction treatment market based on tissue plasminogen activators (tpa), anticoagulants, antiplatelets, anticonvulsants covering the revenue growth of each sub-segment from 2018 to 2030.
The cerebral infarction treatment market in the U.S. is characterized by its technological advancements and emphasis on personalized medicine. The country is at the forefront of adopting innovative therapies, including new anticoagulants and AI-powered diagnostic tools.
According to estimates from the Georgia Department of Public Health in April 2024, stroke is the fifth leading cause of death in Georgia and a major, yet preventable, cause of disability.
Georgia, located in the "stroke belt" of the southeastern U.S., experiences stroke death rates approximately 30.0% higher than the national average. The coastal plains of Georgia, known as the "buckle" of this region, face stroke death rates about 40.0% higher than the rest of the country.
Reasons to subscribe to U.S. cerebral infarction treatment market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of U.S. cerebral infarction treatment market databook
-
Our clientele includes a mix of cerebral infarction treatment market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the U.S. cerebral infarction treatment market , including forecasts for subscribers. This country databook contains high-level insights into U.S. cerebral infarction treatment market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
US Drug Class - Cerebral Infarction Treatment Market size, 2024 - 2030 (US$M)
U.S. Cerebral Infarction Treatment Market Outlook Share, 2024 & 2030 (US$M)
Related industry reports
Related statistics
No records
No related statistics found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
